RSS

adeno-associated viruses (AAV)

German-based company, SIRION Biotech has signed a two-year development agreement with a clinical-stage ophthalmology company, Acucela, to establish optimised adeno associated virus (AAV) vectors for clinical applications in ocular gene therapy. more

News

UK-based synthetic biology company, Oxford Genetics, has established a new agreement with clinical-stage gene therapy company, MeiraGTx, for the development of novel adeno-associated virus (AAV) vectors. more

News

Lonza and Massachusetts Eye and Ear (MEE) have granted Akouos (a new biotechnology company) licences for exclusive rights to the ancestral adeno-associated viral vectors (Anc-AAV) gene therapy platform for all hearing and balance disorders. more

News

Novartis has announced a collaboration with biotech company, Homology Medicines, to adapt and refine the technology for the treatment of a blood disorder and certain eye diseases. more

News